Application of in-line real-time process monitoring using a process analytical technology for granule size distribution can enable quality-by-design development of a drug product and enable attribute-based monitoring and control strategies. In this study, an in-line laser focused beam reflectance measurement (FBRM) C35 probe was used to investigate the effect of formulation and process parameters on the granule growth profile over time during the high shear wet granulation of a high drug load formulation of brivanib alaninate. The probe quantitatively captured changes in the granule chord length distribution (CLD) with the progress of granulation and delineated the impact of water concentration used during granulation. The results correlated well with offline particle size distribution measured by nested sieve analyses. An end point indication algorithm was developed that was able to successfully track the process time needed to reach the target CLD. Testing of the brivanib alaninate granulation through 25-fold scale-up of the batch process indicated that the FBRM CLD profile can provide a scale-independent granule attribute-based process fingerprint. These studies highlight the ability of FBRM to quantitate a granule attribute of interest during wet granulation that can be used as an attribute-based scale-up and process monitoring and control parameter.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.xphs.2016.08.025DOI Listing

Publication Analysis

Top Keywords

brivanib alaninate
12
wet granulation
12
monitoring control
12
application in-line
8
focused beam
8
beam reflectance
8
reflectance measurement
8
process
8
attribute-based monitoring
8
control strategies
8

Similar Publications

Article Synopsis
  • - MCM3, a component of the minichromosome maintenance complex, is significantly overexpressed in pancreatic adenocarcinoma (PAAD) tissues compared to non-PAAD tissues, indicating its potential role in the disease's development.
  • - The study utilized various analytical methods, including mRNA and protein expression analysis, to show that MCM3 is crucial for PAAD growth, influencing processes like DNA replication and cell cycle regulation.
  • - High levels of MCM3 expression in PAAD could be linked to increased sensitivity to specific drugs, suggesting that targeting MCM3 might be a promising strategy for treatment.
View Article and Find Full Text PDF

Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.

Int J Mol Sci

August 2024

Department of Anatomy and Cell Biology, College of Medicine, Gachon University, 155 Getbeol-ro, Yeonsu-gu, Incheon 21999, Republic of Korea.

Article Synopsis
  • Despite advancements in treating hepatocellular carcinoma (HCC), options for patients remain limited, with HCC being the most common liver cancer globally.
  • A systematic review of clinical trials from 2013 to 2023 identified 60 relevant studies on current treatments for HCC in Asian populations, focusing on pharmacological interventions and surgical options.
  • The review highlights that sorafenib, either used alone or in combination with other drugs like atezolizumab and bevacizumab, has been the preferred treatment choice over the past decade for better patient outcomes.
View Article and Find Full Text PDF

Quantification and analyses of seven tyrosine kinase inhibitors targeting hepatocellular carcinoma in human plasma by QuEChERS and UPLC-MS/MS.

J Chromatogr B Analyt Technol Biomed Life Sci

July 2024

College of Pharmacy, Hebei Medical University, Shijiazhuang 050000, China; Hebei Institute of Drug and Medical Device Inspection, Shijiazhuang 050000, China. Electronic address:

Tyrosine kinase inhibitors (TKIs) are commonly used to treat various cancers. Literature suggests that the blood concentration of TKIs strongly correlates with their efficacy and adverse effects. Therefore, establishing a Therapeutic Drug Monitoring (TDM) methodology for TKI drugs is crucial to improving their clinical efficacy and minimizing the treatment-related adverse effects.

View Article and Find Full Text PDF

Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer.

J Cancer

October 2023

NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, PR China.

Ovarian cancer (OC) represents the seventh most lethal female tumors worldwide. The combination of PARP inhibitor (PARPi) and angiogenic inhibitor has been shown to be effective as a first-line or second-line maintenance regimen to synergistically exert antitumor effects, which prompts us to further evaluate the therapeutic effect of the combination of PARP inhibitor Niraparib and anti-angiogenic Brivanib on OC. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay were applied to evaluate the anti-proliferative effect of Niraparib, Brivanib, or the combination treatment on OC cells.

View Article and Find Full Text PDF

Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer.

Clin Colorectal Cancer

December 2023

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto ON. Electronic address:

Background: Cetuximab is a standard of care therapy for patients with RAS wild-type (WT) advanced colorectal cancer. Limited data suggest a wide variation in cetuximab plasma concentrations after standard dosing regimens. We correlated cetuximab plasma concentrations with survival and toxicity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!